Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2008; 99(01): 155-160DOI: 10.1160/TH07-09-0556 Cardiovascular Biology and Cell Signalling Schattauer GmbH Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial Uwe Zeymer 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany 2 Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg , Anselm K Gitt 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany 2 Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg , Claus Jünger 2 Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg , Timm Bauer 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany , Oliver Koeth 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany , Tobias Heer 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany , Bernd Mark 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany , Ralf Zahn 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany , Martin Gottwik 3 Klinikum Nürnberg-Süd, Medizinische Klinik 8, Nürnberg, Germany , Jochen Senges 1 Herzzentrum Ludwigshafen, Medizinsche Klinik B, Ludwigshafen, Germany 2 Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg › Author Affiliations Recommend Article Abstract Full Text PDF Download Keywords KeywordsClopidogrel - reperfusion therapy - primary percutaneous coronary intervention - ST elevation myocardial infarction - prognosis - clinical practice References References 1 Van de Werf F, Ardissino D, Betriu A. et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66. 2 ISIS 2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction. Lancet 1988; 2: 349-360. 3 Herbert JM, Frechel D, Valler E. et al. Clopidogrel, a novel antiplatelet and antithrombotic drug. Cardiovasc Drug Rev 1993; 11: 180-198. 4 The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acue coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. 5 Steinhubl SR, Berger PB, Mann JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420. 6 Sabatine MS, Cannon CP, Gibson CM. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. 7 COMMIT collobarative group.. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621. 8 Sabatine MS, Cannon CP, Gibson CM. et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with St-elevation myocardial infarction. The PCI-CLARITY Study. JAMA 2005; 294: 1224-1232. 9 Zeymer U, Senges J. Qualitätsregister in der Kardiologie. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2004; 47: 533-539. 10 Zeymer U, Gitt AK, Junger C. et al. and the Acute COronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006; 27: 2661-2666. 11 Morrow DA, Antman EM, Charlesworth A. et al. TIMI risk score for St-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an InTIME II trial substudy. Circulation 2000; 102: 2031-2037. 12 Steinhubl SR, Kastrati A, Berger P. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary intervention and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007; 154: 3-11.
